Company
Flightpath
TREATING COMPLEX DISEASE BY ELIMINATING ROOT-CAUSE BACTERIA BEFORE TISSUE DAMAGE BECOMES IRREVERSIBLE
Also known as Flightpath Biosciences
- Status
- Operatingas of 2026-09-21
- Business model
- B2B
- Headquarters
- Detroit, Michigan, United States
Claim, correct or request removal
Record updated 28 September 2026
About
At Flightpath Biosciences, we are dedicated to advancing the science of infection-driven disease and developing a platform designed to interrupt disease before it becomes irreversible. Our goal is to unlock new possibilities for addressing complex diseases and ultimately reshape how they are treated.
Funding snapshot
- Total raised
- $9.6MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $8.1M2023-02-13
Funding rounds
- Round, 2023
- $8.1M2023-02-13, SEC form D sold, 17 investors
- Round, 2020
- $1.5M2020-02-12, SEC form D sold, 1 investor
Products
- Other
- FP100 (hygromycin A)
- Other
- FP530 (forazemin)
Loading relationship preview